Discovery of a Novel Covalent EZH2 Inhibitor Based on Tazemetostat Scaffold for the Treatment of Ovarian Cancer
Journal of Medicinal Chemistry · 2023
DOI: 10.1021/acs.jmedchem.2c01370 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2023. Verfasst von Qiangsheng Zhang und 12 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, and Collaborative Innovation Center of Biotherapy, Sichuan University, 17#…. Hauptthemen laut MEDLINE: Enhancer of Zeste Homolog 2 Protein, Ovarian Neoplasms. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: Department of Science and Technology of Sichuan Province, National Natural Science Foundation of China, Sichuan Cancer Hospital.
Abstract (Originalsprache)
Enhancer of zeste homologue 2 (EZH2) is the enzymatic catalytic subunit of polycomb repressive complex 2 (PRC2), which plays an important role in post-translational modifications of histones. In this study, we designed and synthesized a new series EZH2 covalent inhibitors that have rarely been reported. Biochemical studies and mass spectrometry provide information that SKLB-03220 could covalently bind to the S-adenosylmethionine (SAM) pocket of EZH2. Besides, SKLB-03220 was highly potent for EZH2MUT, while exhibiting weak activities against other tested histone methyltransferases (HMTs) and kinases. Moreover, SKLB-03220 displayed noteworthy potency against ovarian cancer cell lines and continuously abolished H3K27me3 after washing out. Furthermore, oral administration of SKLB-03220 significantly inhibited tumor growth in PA-1 xenograft model without obvious adverse effects. Taken together, SKLB-03220 is a potent, selective EZH2 covalent inhibitor with noteworthy anticancer efficacy both in vitro and in vivo.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, and Collaborative Innovation Center of Biotherapy, Sichuan University, 17#3rd Section, Ren Min South Road, Chengdu 610041, P. R. China.
- College of Chemistry and Life Science, Chengdu Normal University, Chengdu 611130, P. R. China.
- School of Life Science and Engineering, Southwest JiaoTong University, Chengdu 611756, Sichuan, P. R. China.
- Laboratory of Emergency Medicine, Department of Emergency Medicine, West China Hospital, Sichuan University, Chengdu 610041, P. R. China.
- Department of Clinical Pharmacy, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610041, P. R. China.
Förderung
- Department of Science and Technology of Sichuan Province
- National Natural Science Foundation of China
- Sichuan Cancer Hospital
Zitieren
APA
Zhang, Q., Chen, X., Cao, J., Yang, W., Wan, G., Feng, Q., Zhou, S., Yang, H., Wang, N., Liu, Z., Xiao, H., Zhu, Y., & Yu, L. (2023). Discovery of a Novel Covalent EZH2 Inhibitor Based on Tazemetostat Scaffold for the Treatment of Ovarian Cancer. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.2c01370
Vancouver
Zhang Q, Chen X, Cao J, Yang W, Wan G, Feng Q, et al. Discovery of a Novel Covalent EZH2 Inhibitor Based on Tazemetostat Scaffold for the Treatment of Ovarian Cancer. Journal of Medicinal Chemistry. 2023. doi:10.1021/acs.jmedchem.2c01370
BibTeX
@article{Zhang2023,
author = {Zhang, Qiangsheng and Chen, Xinyi and Cao, Jiaying and Yang, Wan and Wan, Guoquan and Feng, Qiang and Zhou, Shuyan and Yang, Hongling and Wang, Ningyu and Liu, Zhihao and Xiao, Hongtao and Zhu, Yongxia and Yu, Luoting},
title = {Discovery of a Novel Covalent EZH2 Inhibitor Based on Tazemetostat Scaffold for the Treatment of Ovarian Cancer},
journal = {Journal of Medicinal Chemistry},
year = {2023},
doi = {10.1021/acs.jmedchem.2c01370}
}
EUVIMED